Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Flanders Innovation & Entrepreneurship
Deal Size : $1.16 million
Deal Type : Funding
Confo Receives VLAIO Grant for Long-Acting Antibody-Based GPCR Therapeutics in Endocrine Conditions
Details : The funding will support the development of an undisclosed antibody targeting GPCR to address obesity.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 08, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Flanders Innovation & Entrepreneurship
Deal Size : $1.16 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery
Sponsor : Driehaus Capital Management
Deal Size : $65.0 million
Deal Type : Series B Financing
Confo Secures EUR 60M Series B for GPCR-Modulating Therapies
Details : The proceeds will be used to advance wholly-owned programs, including molecules targeting GPR75, which is being evaluated in the early-stage clinical trial studies for obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 25, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery
Sponsor : Driehaus Capital Management
Deal Size : $65.0 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Flanders Innovation & Entrepreneurship
Deal Size : $1.7 million
Deal Type : Funding
Confo Secures VLAIO Grant for Drug Discovery in Endocrine and Metabolic Diseases
Details : The net proceeds will be used to expand Confo’s ongoing R&D efforts in the discovery of next-generation medicines targeting Class B GPCRs using its patent-protected technology platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Flanders Innovation & Entrepreneurship
Deal Size : $1.7 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : AbCellera
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, leveraging confo's proprietary ConfoBody® technology to stabilize the selected GPCRs in their disease-relevant conformations.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 15, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : AbCellera
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Confo will lead the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Lilly will continue the clinical development program beyond Phase 1 of CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) for the treatment of neuropathic pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $40.0 million
March 02, 2023
Details : CFTX-1554 is a novel inhibitor of AT2R, a clinically precedented target for the treatment of neuropathic pain. CFTX-1554 interacts more efficiently with the AT2R binding site, resulting in improved properties.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 15, 2022
Details : The grant will enable to further extend its current universal ConfoBody®, Cb35, toward other G proteins. The funds will also be used to identify additional universal ConfoBodies® for use in ConfoSensor® screening technology and lead neuropathic pain p...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 28, 2022
Details : CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R), is being developed as a non-opioid approach to the treatment of neuropathic pain, while avoiding centrally mediated side effects, such as addiction and sedation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2022
Lead Product(s) : CFTX-1554
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of CFTX-1554 in Healthy Subjects
Details : CFTX-1554 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 02, 2022
Lead Product(s) : CFTX-1554
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
